Get started
Author

Katja Marja Hakkarainen

Observed names: Hakkarainen Katja Marja, Hakkarainen, Katja, Hakkarainen, Katja M., Hakkarainen, Katja Marja, K. Hakkarainen, K. M. Hakkarainen, K.M. Hakkarainen, Katja Hakkarainen, Katja M Hakkarainen, Katja M. Hakkarainen
Observed institutions: PAREXEL International (United Kingdom), IQVIA (United Kingdom), Region Jönköpings län, PAREXEL International (United States), PAREXEL International (France), Nordic School of Public Health, Futurum - Akademin för Hälsa och Vård, University of Gothenburg
ORCID: 0000-0002-7313-8532
Observed ORCID: 0000-0002-7313-8532
OpenAlex ID: A5074924616
Percentage of Patients with Preventable Adverse Drug Reactions and Preventability of Adverse Drug Reactions – A Meta-Analysis
2012 · Katja M. Hakkarainen, Khadidja Hedna, et al. · PLoS ONE · 298
PDF
Potentially inappropriate prescribing and adverse drug reactions in the elderly: a population-based study
2015 · Khedidja Hedna, Katja M. Hakkarainen, et al. · European Journal of Clinical Pharmacology · 160
PDF
Metformin in pregnancy and risk of adverse long-term outcomes: a register-based cohort study
2022 · Kerstin M G Brand, Laura Saarelainen, et al. · BMJ Open Diabetes Research & Care · 97
PDF
Economic Impact of Adverse Drug Events – A Retrospective Population-Based Cohort Study of 4970 Adults
2014 · Hanna Gyllensten, Katja M. Hakkarainen, et al. · PLoS ONE · 73
Prevalence, nature and potential preventability of adverse drug events – a population‐based medical record study of 4970 adults
2013 · Katja M. Hakkarainen, Hanna Gyllensten, et al. · British Journal of Clinical Pharmacology · 68
PDF
Methods for Assessing the Preventability of Adverse Drug Events: A Systematic Review
2011 · Katja Marja Hakkarainen, Karolina Andersson Sundell, et al. · Drug Safety · 67
Adherence to Antihypertensive Therapy and Elevated Blood Pressure: Should We Consider the Use of Multiple Medications?
2015 · Khedidja Hedna, Katja M. Hakkarainen, et al. · PLoS ONE · 61
PDF
Curriculum Reform in Finnish Pharmacy Education
2009 · Nina Katajavuori, Katja Hakkarainen, et al. · American Journal of Pharmaceutical Education · 50
Prevalence and Perceived Preventability of Self-Reported Adverse Drug Events – A Population-Based Survey of 7099 Adults
2013 · Katja Marja Hakkarainen, Karolina Andersson Sundell, et al. · PLoS ONE · 49
PDF
Prenatal exposure to pregabalin, birth outcomes and neurodevelopment – a population-based cohort study in four Nordic countries
2023 · Elena Dudukina, Szimonetta Komjáthiné Szépligeti, et al. · Drug Safety · 40
PDF
Pregnancy outcomes after exposure to interferon beta: a register-based cohort study among women with MS in Finland and Sweden
2020 · Katja Marja Hakkarainen, Rosa Juuti, et al. · Therapeutic Advances in Neurological Disorders · 35
Healthcare costs of adverse drug reactions and potentially inappropriate prescribing in older adults: a population-based study
2022 · Eirin Guldsten Robinson, Khedidja Hedna, et al. · BMJ Open · 28
PDF
Preventable drug related mortality in a Swedish population
2009 · Anna K. Jönsson, Katja M. Hakkarainen, et al. · Pharmacoepidemiology and Drug Safety · 28
The impact of a changed legislation on reporting of adverse drug reactions in Sweden, with focus on nurses’ reporting
2015 · Sofia A. Karlsson, Ingela Jacobsson, et al. · European Journal of Clinical Pharmacology · 20
Prevalence of adverse pregnancy outcomes after exposure to interferon beta prior to or during pregnancy in women with MS: Stratification by maternal and newborn characteristics in a register-based cohort study in Finland and Sweden
2020 · Marta Korjagina, Katja M Hakkarainen, et al. · Multiple Sclerosis and Related Disorders · 16
Modelling drug-related morbidity in Sweden using an expert panel of pharmacists’
2012 · Hanna Gyllensten, Katja M. Hakkarainen, et al. · International Journal of Clinical Pharmacy · 12
Modelling drug-related morbidity in Sweden using an expert panel of physicians
2012 · Katja M. Hakkarainen, Daniel Alström, et al. · European Journal of Clinical Pharmacology · 11
Comparing Methods for Estimating Direct Costs of Adverse Drug Events
2017 · Hanna Gyllensten, Anna K. Jönsson, et al. · Value in Health · 10
Refill adherence and self‐reported adverse drug reactions and sub‐therapeutic effects: a population‐based study
2013 · Khedidja Hedna, Staffan Hägg, et al. · Pharmacoepidemiology and Drug Safety · 10
Metformin in pregnancy and risk of abnormal growth outcomes at birth: a register-based cohort study
2022 · Kerstin MG Brand, Robyn Thoren, et al. · BMJ Open Diabetes Research & Care · 8
PDF
Observational evidence from patients diagnosed with chronic lymphocytic leukaemia (CLL) in Finland between 2005‐2015 show improved survival over time
2019 · Vesa Lindström, Katja M. Hakkarainen, et al. · European Journal Of Haematology · 4
PDF
Direct and indirect costs for adverse drug events identified in medical records across care levels, and their distribution among payers
2016 · Jennie Natanaelsson, Katja M. Hakkarainen, et al. · Research in Social and Administrative Pharmacy · 4
Vortioxetine in the routine management of major depressive disorder: an analysis of European automated healthcare databases
2025 · Frank Andersohn, Michael Cronquist Christensen, et al. · Current Medical Research and Opinion · 3
PDF
Inform Interferon Beta Exposure in the 2nd and 3rd Trimester of Pregnancy: A Register-Based Drug Utilisation Study in Finland and Sweden
2022 · Meritxell Sabidó Espin, Kiliana Suzart-Woischnik, et al. · Multiple Sclerosis and Related Disorders · 3
PDF
Prevalence and nature of adverse drug events and the potential for their prevention - Population-based studies among adults
2014 · Hakkarainen Katja Marja · 3
Works count: 55
Citation count: 1,166
H-index: 15
I10-index: 19
Year
Topic
Type